GLP-1 receptor agonists are extensively used in the treatment of type 2 diabetes and obesity and are also emerging as a promising therapy to maintain residual beta cell function in newly diagnosed type 1 diabetes [16, 17]. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.